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Fig. S1. Analytical HPLC chromatogram of the dichloromethane extract of fresh aerial parts of 
Leucophyta brownii at 210 nm (Peak numbers 110 in the HPLC chromatogram refer to 
compound numbers).  
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4-Hydroxy-5H,10H-1,11(13)-guaidien-8,12-olide (1) 
Colorless resin-like oil; []D
25 +153 (c 0.4, MeOH); UV (MeOH) max (log ) 205 (3.66) nm;
 IR 
(KBr) max 3338, 2926, 1771, 1660, 1110 cm
-1 APCIMS: m/z 249 [M + H]+ (14), 231  [M + H  
H2O]
+ (100); HRESIMS m/z 249.1489 (calcd for C15H21O3, 249.1491).  
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Fig. S2. 1H NMR (400 MHz, CDCl3) spectrum of compound 1. 
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Fig. S3. 1H NMR (400 MHz, CDCl3) spectrum of compound 1 expanded in the region 1.14.0 
ppm. 
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Fig. S4. 13C NMR (100 MHz, CDCl3) spectrum of compound 1. 
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Fig. S5. DEPT spectrum of compound 1. 
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Fig. S6. 1H1H COSY spectrum of compound 1. 
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Fig. S7. NOESY spectrum of compound 1. 
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Fig. S8. HSQC spectrum of compound 1. 
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Fig. S9. HMBC spectrum of compound 1. 
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4,10-Dihydroxy-5H-1,11(13)-guaidien-8,12-olide (2) 
Colorless needle-like crystals; mp 169170 oC; []D
25 +34 (c 0.4, MeOH); UV (MeOH) max (log ) 
209 (3.84) nm; IR (KBr) max 3338, 2941, 1758, 1655, 1380, 1273, 1169 cm
-1. APCIMS: m/z 265 
[M + H]+ (8), 247  [M  H2O + H]
+ (51),  229  [M  2 H2O + H]
+ (100); HRESIMS m/z 265.1441 
(calcd for C15H21O4, 265.1440). 
 
 
 
 
 
 
 
 
 
 
 
Fig. S10. Crystal structure of compound 2 (ORTEP diagram) with displacement ellipsoids at 50% 
probability for non-H atoms. 
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Fig. S11. 1H NMR (400 MHz, methanol-d4) spectrum of compound 2. 
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Fig. S12. 13C NMR (100 MHz, methanol-d4) spectrum of compound 2. 
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Fig. S13. DEPT spectrum of compound 2. 
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Fig. S14. 1H1H COSY spectrum of compound 2. 
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Fig. S15. NOESY spectrum of compound 2. 
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Fig. S16. HSQC spectrum of compound 2. 
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Fig. S17. HMBC spectrum of compound 2. 
 
 
 
 
 
 
 
 
 
 
HMBC 
2 
23 
 
4-Hydroxy-1,2-epoxy-5H,10H-11(13)-guaien-8,12-olide (3) 
Colorless crystals; mp 168169 oC; []D
25 +31 (c 0.4, CHCl3); UV (MeOH) max (log ) 210 (4.11) 
nm; IR (KBr) max 3497, 2949, 1757, 1658, 1398, 1271, 1131 cm
-1; APCIMS: m/z 265 [M + H]+ 
(13), 247  [M  H2O + H]
+ (39),  229 [M  2 H2O + H]
+ (100); HRESIMS m/z 265.1440 (calcd for 
C15H21O4, 265.1440). 
 
 
 
 
Fig. S18. Crystal structure of compound 3 (ORTEP diagram) with displacement ellipsoids at 50% 
probability for non-H atoms. 
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Fig. S19. 1H NMR (400 MHz, CDCl3) spectrum of compound 3. 
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Fig. S20. 1H NMR (400 MHz, CDCl3) spectrum of compound 3 expanded in the region 1.34.2 
ppm. 
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Fig. S21. 13C NMR (100 MHz, CDCl3) spectrum of compound 3. 
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Fig. S22. DEPT spectrum of compound 3. 
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Fig. S23. 1H1H COSY spectrum of compound 3. 
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Fig. S24. NOESY spectrum of compound 3. 
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Fig. S25. HSQC spectrum of compound 3. 
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Fig. S26. HMBC spectrum of compound 3. 
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Calocephalin [4-acetoxy-1,2-epoxy-5H,10H-11(13)-guaien-8,12-olide] (4)  
Colorless crystals; mp 125126 oC; []D
25 +14 (c 0.4, CHCl3); UV (MeOH) (log ) 212 (4.12) nm; IR 
(KBr) max 3425, 2920, 1746, 1716, 1657, 1459, 1370, 1263, 1115, 1007 cm
-1; APCIMS: m/z 307 
[M + H]+ (23), 264 [M + H  Ac]+ (16),  247 [M + H  HOAc]+ (100),  229 [M + H  HOAc  H2O]
+ 
(93); HRESIMS m/z 307.1540 (calcd for C17H23O5, 307.1546). 
 
 
 
 
 
 
 
 
 
 
Fig. S27. Crystal structure of calocephalin (4) [ORTEP diagram] with displacement ellipsoids at 
50% probability for non-H atoms. 
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Fig. S28. 1H NMR (400 MHz, CDCl3) spectrum of calocephalin (4). 
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Fig. S29. 1H NMR (400 MHz, CDCl3) spectrum of calocephalin (4) expanded in the region 
0.833.97 ppm.  
 
 
 
 
 
 
 
 
1
H NMR 
 4 
 
35 
 
 
 
Fig. S30. 13C NMR (100 MHz, CDCl3) spectrum of calocephalin (4). 
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Fig. S31. DEPT spectrum of calocephalin (4). 
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Fig. S32. 1H1H COSY spectrum of calocephalin (4). 
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Fig. S33. NOESY spectrum of calocephalin (4). 
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Fig. S34. HSQC spectrum of calocephalin (4). 
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Fig. S35. HMBC spectrum of calocephalin (4). 
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Fig. S36. 1H NMR (400 MHz, CDCl3) spectrum of the new compound 5. 
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Fig. S37. 1H NMR (400 MHz, CDCl3) spectrum of the new compound 5 expanded in the region 
3.045.26 ppm. 
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Fig. S38. 1H NMR (400 MHz, CDCl3) spectrum of the new compound 5 expanded in the region 
0.93.0 ppm. 
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Fig. S39. 13C NMR (100 MHz, CDCl3) spectrum of the new compound 5. 
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Fig. S40. DEPT spectrum of the new compound 5. 
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Fig. S41. 1H1H COSY spectrum of the new compound 5. 
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Fig. S42. NOESY spectrum of the new compound 5. 
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Fig. S43. HSQC spectrum of the new compound 5. 
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Fig. S44. HMBC spectrum of the new compound 5. 
 
 
 
 
 
 
 
 
 
 
HMBC 
5 
50 
 
 
 
Fig. S45. 1H NMR (400 MHz, methanol-d4) spectrum of the new compound 6. 
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Fig. S46. 1H NMR (400 MHz, methanol-d4) spectrum of the new compound 6 expanded in the 
region 0.954.15 ppm. 
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Fig. S47. 13C NMR (100 MHz, methanol-d4) spectrum of the new compound 6. 
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Fig. S48. DEPT spectrum of the new compound 6. 
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Fig. S49. 1H1H COSY spectrum of the new compound 6. 
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Fig. S50. NOESY spectrum of the new compound 6. 
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Fig. S51. HSQC spectrum of the new compound 6. 
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Fig. S52. HMBC spectrum of the new compound 6. 
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Pseudoivalin [4-hydroxy-5H-10,11(13)-guaidien-8,12-olide] (7) 
Colorless crystals; mp 121122 oC; []D
25 146 (c 0.4, CHCl3); UV (MeOH) max (log ) 214 (4.15) 
nm; IR (KBr) max 3578, 3342, 2971, 1772, 1754, 1640, 1308, 1105 cm
-1; APCIMS: m/z 249 [M + 
H]+ (21),  231  [M + H  H2O]
+ (100); HRESIMS m/z 249.1487 (calcd for C15H21O3, 249.1491). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S53. Crystal structure of pseudoivalin (7) [ORTEP diagram] with displacement 
ellipsoids at 50% probability for non-H atoms. 
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Fig. S54. 1H NMR (400 MHz, CDCl3) spectrum of pseudoivalin (7). 
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Fig. S55. 1H NMR (400 MHz, CDCl3) spectrum of pseudoivalin (7) expanded in the region 
1.353.98 ppm. 
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Fig. S56. 13C NMR (100 MHz, CDCl3) spectrum of pseudoivalin (7). 
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Fig. S57. DEPT spectrum of pseudoivalin (7). 
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Fig. S58. 1H1H COSY spectrum of pseudoivalin (7). 
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Fig. S59. NOESY spectrum of pseudoivalin (7). 
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Fig. S60. HSQC spectrum of pseudoivalin (7). 
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Fig. S61. HMBC spectrum of pseudoivalin (7). 
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Pseudoivalin acetate [4-acetoxy-5H-10,11(13)-guaidien-8,12-olide] (8) 
Colorless crystals; mp 160161 oC; []D
25 164 (c 0.4, CHCl3); UV (MeOH) max (log ) 207 (4.05) 
nm; IR (KBr) max 3430, 2942, 1766, 1725, 1664, 1373, 1260, 1117, 1060 cm
-1; APCIMS: m/z 248 
[M + H  Ac]+ (21),  231  [M + H  HOAc]+ (100); HRESIMS m/z 313.1408 (calcd for C17H22O4Na, 
313.1416). 
 
 
 
 
 
 
 
 
 
Fig. S62. Crystal structure of pseudoivalin acetate (8) [ORTEP diagram] with displacement 
ellipsoids at 50% probability for non-H atoms. 
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Fig. S63. 1H NMR (400 MHz, CDCl3) spectrum of pseudoivalin acetate (8). 
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Fig. S64. 1H NMR (400 MHz, CDCl3) spectrum of pseudoivalin acetate (8) expanded in the region 
1.033.98 ppm. 
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Fig. S65. 13C NMR (100 MHz, CDCl3) spectrum of pseudoivalin acetate (8). 
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Fig. S66. DEPT spectrum of pseudoivalin acetate (8). 
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Fig. S67. 1H1H COSY spectrum of pseudoivalin acetate (8). 
 
 
 
 
 
 
 
 
 
 
COSY 
8 
73 
 
 
 
Fig. S68. NOESY spectrum of pseudoivalin acetate (8). 
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Fig. S69. HSQC spectrum of pseudoivalin acetate (8). 
 
 
 
 
 
 
 
 
 
 
HSQC 
8 
75 
 
 
 
Fig. S70. HMBC spectrum of pseudoivalin acetate (8). 
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Tomentosin (9) 
Colorless oil; []D
25 +8 (c 0.4, CHCl3); UV (MeOH) max (log ) 215 (4.12) nm;
 APCIMS: m/z 249 
[M + H]+ (100), 231 [M + H  H2O]
+ (65); HRESIMS m/z 249.1490 (calcd for C15H21O3, 249.1491). 
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Fig. S71. 1H NMR (400 MHz, CDCl3) spectrum of tomentosin (9). 
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Fig. S72. 1H NMR (400 MHz, CDCl3) spectrum of tomentosin (9) expanded in the region 
1.783.98 ppm. 
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Fig. S73. 13C NMR (100 MHz, CDCl3) spectrum of tomentosin (9). 
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Fig. S74. DEPT spectrum of tomentosin (9). 
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Fig. S75. 1H1H COSY spectrum of tomentosin (9). 
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Fig. S76. NOESY spectrum of tomentosin (9). 
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Fig. S77. HSQC spectrum of tomentosin (9). 
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Fig. S78. HMBC spectrum of tomentosin (9). 
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Fig. S79. 1H NMR (400 MHz, CDCl3) spectrum of the new compound 10. 
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Fig. S80. 1H NMR (400 MHz, CDCl3) spectrum of the new compound 10 expanded in the region 
0.883.15 ppm. 
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Fig. S81. 13C NMR (100 MHz, CDCl3) spectrum of the new compound 10.
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Fig. S82. DEPT spectrum of the new compound 10. 
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Fig. S83. 1H1H COSY spectrum of the new compound 10. 
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Fig. S84. NOESY spectrum of the new compound 10. 
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Fig. S85. HSQC spectrum of the new compound 10. 
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Fig. S86. HMBC spectrum of the new compound 10. 
 
 
 
 
 
 
 
 
 
 
HMBC 
10 
